文献速递系统性红斑狼疮

瑞典20年系统性红斑狼疮妊娠不良结局与治疗趋势

Nationwide Temporal Trends in Adverse Pregnancy Outcomes and Treatments in Systemic Lupus Erythematosus Pregnancy Over Two Decades in Sweden.
PubMed 文献 · Arthritis Rheumatol · 2026-02-19

该全国性描述性研究基于瑞典登记数据,纳入2003至2022年1417例SLE妊娠并与14133例非SLE妊娠匹配,分析不良妊娠结局及治疗随时间的变化。SLE妊娠中子痫前期、早产和小于胎龄儿比例下降,抗疟药和小剂量阿司匹林使用增加,糖皮质激素使用略降。

要点

  • SLE妊娠中子痫前期、早产和小于胎龄儿比例在20年间下降。
  • 抗疟药使用从23.9%升至76.5%,小剂量阿司匹林从39.8%升至85.6%。
  • 糖皮质激素使用从43.2%略降至40.1%。

核心结论

  • SLE妊娠不良妊娠结局在过去二十年下降,可能反映治疗策略改善,尤其是抗疟药和小剂量阿司匹林使用增加。

研究设计与样本

  • 基于瑞典全国登记的描述性研究,纳入1417例SLE妊娠和14133例按母亲年龄、分娩年份和产次匹配的非SLE妊娠,覆盖2003至2022年。

主要发现

  • 2003-2022年SLE妊娠总体子痫前期9.1%、早产14.7%、小于胎龄儿6.9%。
  • SLE妊娠中子痫前期从2003-2004年14.1%降至2021-2022年9.6%,年绝对变化-0.11个百分点。
  • SLE妊娠中早产从25.9%降至11.2%,年绝对变化-0.63个百分点;小于胎龄儿从10.6%降至7.0%,年绝对变化-0.22个百分点。
  • 一般人群不良妊娠结局保持稳定;初产SLE妊娠下降比经产更明显;合并抗磷脂综合征的SLE妊娠不良结局适度下降。

关键数值与推荐

  • 2007-2008至2021-2022年,妊娠期抗疟药使用从23.9%升至76.5%,年绝对变化+3.3个百分点。
  • 妊娠期小剂量阿司匹林使用从39.8%升至85.6%,年绝对变化+3.7个百分点。
  • 妊娠期糖皮质激素使用从43.2%降至40.1%,年绝对变化-0.7个百分点。

临床怎么用

  • SLE妊娠管理可参考抗疟药和小剂量阿司匹林使用增加与不良妊娠结局下降的关联,但需结合个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003 to 2022. METHODS: Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003 to 2022 and matched them to 14,133 non-SLE pregnancies from the general population on maternal age, delivery year, and parity. We assessed proportions of preeclampsia, preterm delivery, and small for gestational age (SGA) birth over time. Antimalarial, glucocorticoid, and low-dose aspirin use were examined during 2007 to 2022. Binomial generalized linear models with an identity link quantified mean annual absolute change (expressed in percentage points [pp]) in APO and treatment proportions. RESULTS: Overall, SLE pregnancies had 9.1% preeclampsia, 14.7% preterm delivery, and 6.9% SGA births (2003-2022). These outcomes remained stable in the general population but decreased in SLE pregnancies (preeclampsia from 14.1% in 2003-2004 to 9.6% in 2021-2022, -0.11 pp/y; preterm delivery from 25.9% to 11.2%, -0.63 pp/y; and SGA birth from 10.6% to 7.0%, -0.22 pp/y). Declines were more pronounced in nulliparous versus parous SLE pregnancies. APOs modestly decreased over time in SLE pregnancies with antiphospholipid syndrome. Antimalarial use during pregnancy increased from 23.9% in 2007-2008 to 76.5% in 2021-2022 (+3.3 pp/y). Low-dose aspirin use during pregnancy rose from 39.8% to 85.6% (+3.7 pp/y), whereas glucocorticoid use slightly decreased from 43.2% to 40.1% (-0.7 pp/y). CONCLUSION: APOs in SLE pregnancies have decreased over the past two decades, potentially reflecting improved treatment strategies, particularly increased use of antimalarials and low-dose aspirin.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Nguyen NV, Sandström A, Dominicus A, et al. Nationwide Temporal Trends in Adverse Pregnancy Outcomes and Treatments in Systemic Lupus Erythematosus Pregnancy Over Two Decades in Sweden. Arthritis Rheumatol. 2026. PMID: 41429597. doi:10.1002/art.70018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。